Richard Moriggl
Salzburg, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 170 publications
Correction: Cell‑autonomous IL6ST activation suppresses prostate cancer development via STAT3/ARF/p53‑driven senescence and confers an immune‑active tumor microenvironment.
Journal: Molecular cancer
Published: July 07, 2026
STAT1/3/5 Functions Driving Lipid and Energy Metabolism in Cancer and Immunity.
Journal: International journal of molecular sciences
Published: January 30, 2026
Preclinical models of hepatosplenic γδ T-cell lymphoma with an activating STAT5B mutation display sensitivity to JAK inhibitor upadacitinib.
Journal: HemaSphere
Published: October 27, 2025
Somatic STAT5BN642H mutations shape variable immune landscapes resulting in heterogenous immune diseases.
Journal: The Journal of allergy and clinical immunology
Published: September 09, 2025
IQDMA disrupts STAT5 nuclear transport through CDC42-PAK2 axis collapse in cutaneous T-cell lymphoma.
Journal: Frontiers in immunology
Published: August 15, 2025
Corrigendum to "Monogenic deficiency in murine intestinal Cdc42 leads to mucosal inflammation that induces crypt dysplasia" [Genes & Dis 11 (2024) 413-429].
Journal: Genes & diseases
Published: July 03, 2025
Thyroid hormone receptor beta signaling is a targetable driver of prostate cancer growth.
Journal: Molecular cancer
Published: April 14, 2025
Monoselective Histone Deacetylase 6 PROTAC Degrader Shows In Vivo Tractability.
Journal: Journal of medicinal chemistry
Published: March 10, 2025
Multiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery.
Journal: Cancer research
Published: February 27, 2025
Last Updated: 09/26/2026